Pay in 4 interest-free payments of $5.68 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Drugs that activate the GLP-1 receptor are available on the market as treatments for T2DM or obesity
The high-dose version is already approved in the EU in a vial formulation under the Wegovy HD brand name, and is another important line extension for Novo Nordisk as it tries to protect its weight-loss franchise from Lilly's rival injectable Zepbound/Mounjaro (tirzepatide)
A 50-year-old patient will come in, and suddenly, shes super-skinny and needs filler, which she never needed before
Participants receiving the highest dose lost significantly more weight compared to placebo groups, with benefits sustained as long as treatment continued
US$ 28.43
US$ 21.03
US$ 23.14
US$ 29.47
US$ 27.78
US$ 24.85
US$ 22.63
US$ 24.59
US$ 22.26
